Australia Plasmid Dna Contract Manufacturing Market Size & Outlook
Related Markets
Australia plasmid dna contract manufacturing market highlights
- The Australia plasmid dna contract manufacturing market generated a revenue of USD 3.4 million in 2023 and is expected to reach USD 12.2 million by 2030.
- The Australia market is expected to grow at a CAGR of 20.3% from 2024 to 2030.
- In terms of segment, cell & gene therapy was the largest revenue generating application in 2023.
- Cell & Gene Therapy is the most lucrative application segment registering the fastest growth during the forecast period.
Plasmid dna contract manufacturing market data book summary
| Market revenue in 2023 | USD 3.4 million |
| Market revenue in 2030 | USD 12.2 million |
| Growth rate | 20.3% (CAGR from 2023 to 2030) |
| Largest segment | Cell & gene therapy |
| Fastest growing segment | Cell & Gene Therapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cell & Gene Therapy, Immunotherapy |
| Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
Other key industry trends
- In terms of revenue, Australia accounted for 1.0% of the global plasmid dna contract manufacturing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China plasmid dna contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 37.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Plasmid DNA Contract Manufacturing Market Scope
Plasmid DNA Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Esco Aster | View profile | 11-50 | Singapore, Central Region, Singapore, Asia | https://escoaster.com |
| PlasmidFactory | View profile | 11-50 | Bielefeld, Nordrhein-Westfalen, Germany, Europe | https://plasmidfactory.com/ |
| VGXI | View profile | 101-250 | The Woodlands, Texas, United States, North America | https://vgxii.com/ |
| Viva Biotech | View profile | 1001-5000 | Shanghai, Shanghai, China, Asia | http://www.vivabiotech.com.cn/ |
| BioCina | View profile | 101-250 | Thebarton, South Australia, Australia, Oceania | https://www.biocina.com/ |
| TriLink BioTechnologies | View profile | 251-500 | San Diego, California, United States, North America | http://www.trilinkbiotech.com/ |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Australia plasmid dna contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 58.82% in 2023. Horizon Databook has segmented the Australia plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The growing popularity of gene therapies and increasing prevalence if chronic diseases are the key factors driving the market. According to Australian Bureau of Statistics, nearly half of the Australians, irrespective of age, had at least one chronic disease (46.6%) and nearly one in five (18.6%) had two or more.
One in five (20.7%) females had two or more chronic diseases, and nearly half (49.0%) of all females had one or more chronic conditions. However, Cell, tissue, and gene therapies are newly regulated in the country, and the regulatory framework for biological medicinal products was first introduced in 2011.
Reasons to subscribe to Australia plasmid dna contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia plasmid dna contract manufacturing market databook
-
Our clientele includes a mix of plasmid dna contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Australia plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia plasmid dna contract manufacturing market size, by end user, 2018-2030 (US$M)
Australia Plasmid DNA Contract Manufacturing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
